We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

62 hedge funds and large institutions have $119M invested in Prelude Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.98% less ownership

Funds ownership: 71.61% → 68.63% (-3%)

9% less funds holding

Funds holding: 68 → 62 (-6)

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

27% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 22

50% less capital invested

Capital invested by funds: $235M → $119M (-$117M)

Holders
62
Holders Change
-6
Holders Change %
-8.82%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
16
Reduced
22
Closed
17
Calls
$2.15M
Puts
–
Net Calls
+$2.15M
Net Calls Change
+$655K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$613K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$556K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$502K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$470K
5
CANY
Caxton Associates (New York)
New York
+$427K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.44M
2
BlackRock
BlackRock
New York
-$2.66M
3
State Street
State Street
Massachusetts
-$845K
4
N
Nuveen
North Carolina
-$490K
5
Northern Trust
Northern Trust
Illinois
-$411K
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
76
Credit Suisse
Switzerland
– +$31 +6 New
CAL
77
Capital Advisors Ltd
Ohio
– +$56 +11 New
1 2 3
4

PRLD Hedge Fund Activity: Q2 2022 in Review

62 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q2 2022, worth a combined $119M — down 50% from $235M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PRLD and 13 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 16 added.

The largest buyer was Renaissance Technologies, adding an estimated $613K. The largest seller was Fidelity Investments, cutting an estimated $5.44M.

  • 62 institutional investors held Prelude Therapeutics (PRLD) as of Q2 2022, down from 68 in Q1 2022.
  • Funds reported $119M of Prelude Therapeutics stock for Q2 2022, down 50% quarter-over-quarter.
  • 13 funds opened new Prelude Therapeutics positions in Q2 2022 and 17 closed out, a net change of -4 holders.
  • The largest Prelude Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $613K added.
  • The largest Prelude Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $5.44M sold.

Based on aggregated 13F filings for Q2 2022.